Biology and genetics

Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing. Gralewski JH et al. Diagn Pathol. 2018 Feb 20;13(1):15. doi: 10.1186/s13000-018-0692-1. The transmembrane protein TMEPAI induces myeloma cell apoptosis by promoting degradation of the c-Maf transcription factor. Du Y et al. J Biol Chem. 2018 Feb 21. pii: jbc.RA117.000972. doi: 10.1074/jbc.RA117.000972. [Epub ahead of print]. Loss of heterozygosity…

Details
Journal, Library, Management of Myeloma

Results from Phase III ALCYONE trial published

The results from the Phase III ALCYONE trial have recently been published in The New England Journal of Medicine. The study compared daratumumab (Darzalex®) in combination with bortezomib (Velcade®), melphalan and prednisone (VMP) to VMP alone in newly diagnosed myeloma patients, ineligible for a stem cell transplant. The results show that the 18-month progression-free survival…

Details
News

Phase III pomalidomide trial reaches primary endpoint

Celgene has announced that its Phase III trial, OPTIMISMM, has achieved its primary endpoint of improving progression-free survival (PFS) in patients with relapsed or refractory myeloma. The study compared pomalidomide (Imnovid®) in combination with bortezomib (Velcade®) and low-dose dexamethasone to bortezomib and low-dose dexamethasone in myeloma patients who had received 1 – 3 prior treatments,…

Details
News

Carfilzomib combinations demonstrate overall survival benefit in relapsed and refractory myeloma

Results from the Phase III ASPIRE trial show that carfilzomib (Kyprolis®) in combination with lenalidomide (Revlimid®) and dexamethasone has a significant overall survival (OS) benefit in relapsed and refractory myeloma patients. Recently published in the Journal of Clinical Oncology, the results demonstrate that patients receiving carfilzomib, lenalidomide and dexamethasone had a median OS of 48.3…

Details
News

Supportive treatments

Orchestration of Chemomobilization and G-CSF Administration for Successful Hematopoietic Stem Cell Collection. Kriegsmann K et al. Biol Blood Marrow Transplant. 2018 Jan 15. pii: S1083-8791(18)30022-3. doi: 10.1016/j.bbmt.2018.01.007. [Epub ahead of print]. Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. Anderson K et al. J Clin Oncol. 2018 Jan 17:JCO2017766402. doi: 10.1200/JCO.2017.76.6402. [Epub ahead of…

Details
Journal, Library, Myeloma Prognosis & Outcomes

Related conditions

Role of IRF4 in resistance to immunomodulatory (IMid) compounds® in Waldenström’s macroglobulinemia. Bertrand E et al. Oncotarget. 2017 Dec 4;8(68):112917-112927. doi: 10.18632/oncotarget.22872. eCollection 2017 Dec 22. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. Kyle RA et al. N Engl J Med. 2018 Jan 18;378(3):241-249. doi: 10.1056/NEJMoa1709974. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert…

Details
Journal, Library

General

EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma. Tzogani K et al. Oncologist. 2018 Jan 25. pii: theoncologist.2017-0328. doi: 10.1634/theoncologist.2017-0328. [Epub ahead of print]. Immunopathogenesis and immunotherapy of multiple myeloma. Tamura H et al. Int J Hematol. 2018 Jan 24. doi: 10.1007/s12185-018-2405-7. [Epub ahead of print]. Survival of ethnic and racial minority patients with multiple myelomatreated with newer medications.…

Details
Journal, Library

Emerging treatments

Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma(Kmm150). Jung SH et al. Biol Blood Marrow Transplant. 2018 Jan 12. pii: S1083-8791(18)30019-3. doi: 10.1016/j.bbmt.2018.01.004. [Epub ahead of print]. The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma. Comeau JM et al. Am J Health Syst Pharm. 2018…

Details
Journal, Library

Diagnostic techniques and prognostic indicators

Prognostic Value of IL-10 and Its Relationship with Disease Stage in Iranian Patients with Multiple Myeloma. Shekarriz R et al.Asian Pac J Cancer Prev. 2018 Jan 27;19(1):27-32. Discriminating Depth of Response to Therapy in Multiple Myeloma Using Whole-body Diffusion-weighted MRI with Apparent Diffusion Coefficient: Preliminary Results From a Single-center Study. Wu C et al. Acad Radiol. 2018 Jan 16. pii: S1076-6332(17)30518-4. doi: 10.1016/j.acra.2017.12.008.…

Details
Diagnosing and Monitoring Myeloma, Journal, Library

Current treatments

Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. Dhakal B et al. JAMA Oncol. 2018 Jan 4. doi: 10.1001/jamaoncol.2017.4600. [Epub ahead of print]. Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. Gertz MA et al. Mayo Clin Proc. 2018 Jan;93(1):56-58. doi: 10.1016/j.mayocp.2017.09.012. Prolonged survival after second autologous transplantation and lenalidomide maintenance…

Details
Journal, Library